WhisperSom, founded with a mission to revolutionize sleep apnea treatment, focuses on developing biomedical devices that diagnose, treat, and monitor sleep apnea through personalized neurostimulation. Their core product is a patented, non-invasive medical device aimed at improving breathing during sleep, which is currently progressing through the FDA De Novo pathway. WhisperSom's vision is to enhance the health and quality of life for millions affected by sleep apnea, a condition linked to severe health issues such as diabetes, stroke, and heart disease.

Notable affiliated individuals and investors include key figures in biomedical engineering and healthcare innovation, although specific names are not disclosed. WhisperSom has achieved significant milestones, including the development of their patented technology and advancing towards FDA approval. The company's impact lies in its potential to offer a comfortable, effective alternative to traditional sleep apnea treatments, promising improved patient outcomes and addressing a critical global health challenge.